Jim Cramer Discusses These 12 Stocks & Trump DOJ’s Action Against Health Insurance Companies

1. Novo Nordisk A/S (NYSE:NVO)

Number of Hedge Fund Holders In Q4 2024: 64

Novo Nordisk A/S (NYSE:NVO) is a Danish pharmaceutical firm that is a key part of the global weight loss drug industry. Consequently, weight loss drugs are a key part of its hypothesis. This dependence was clear in December when Novo Nordisk A/S (NYSE:NVO)’s shares dipped by 20% after the firm’s weight loss drug trial missed investor estimates. In 2025, the stock is flat after having struggled due to worries about tariffs. However, Novo Nordisk A/S (NYSE:NVO)’s stock rose by 5% in February after the FDA announced that weight loss drug supply constraints were over. Here is what Cramer said:

“By the way, Wegovy’s no longer in short supply and people are taking up Lilly. I [inaudible] Wegovy down and I think that’s probably, I’m not sure that’s necessarily the, the right thing with Lilly.”

NVO is a stock Jim Cramer recently discussed. While we acknowledge the potential of NVO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than NVO but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap

Disclosure. None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and investors. Please subscribe to our daily free newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.